Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Checkpoint Therapeutics, Inc. (CKPT : NSDQ)
 
 • Company Description   
Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City.

Number of Employees: 14

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.43 Daily Weekly Monthly
20 Day Moving Average: 633,814 shares
Shares Outstanding: 90.59 (millions)
Market Capitalization: $129.54 (millions)
Beta: 1.71
52 Week High: $4.64
52 Week Low: $0.96
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 5.93% 19.29%
12 Week -22.70% -15.03%
Year To Date -54.02% -45.39%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
95 SAWYER ROAD SUITE 110
-
WALTHAM,MA 02453
USA
ph: 781-652-4500
fax: -
arr@lifesciadvisors.com http://www.checkpointtx.com
 
 • General Corporate Information   
Officers
James F. Oliviero - Chief Executive Officer; President and Director
Michael S. Weiss - Chairman
Garrett Gray - Chief Financial Officer
Lindsay A. Rosenwald - Director
Scott Boilen - Director

Peer Information
Checkpoint Therapeutics, Inc. (CORR.)
Checkpoint Therapeutics, Inc. (RSPI)
Checkpoint Therapeutics, Inc. (CGXP)
Checkpoint Therapeutics, Inc. (BGEN)
Checkpoint Therapeutics, Inc. (GTBP)
Checkpoint Therapeutics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 162828107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 90.59
Most Recent Split Date: (:1)
Beta: 1.71
Market Capitalization: $129.54 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.69 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 6.41
Price/Cash Flow: -
Price / Sales: 514.06
EPS Growth
vs. Year Ago Period: -122.22%
vs. Previous Quarter: 48.72%
Sales Growth
vs. Year Ago Period: -23.53%
vs. Previous Quarter: 225.00%
ROE
03/31/22 - -173.15
12/31/21 - -120.09
09/30/21 - -76.42
ROA
03/31/22 - -118.75
12/31/21 - -92.81
09/30/21 - -64.28
Current Ratio
03/31/22 - 1.89
12/31/21 - 2.14
09/30/21 - 4.69
Quick Ratio
03/31/22 - 1.89
12/31/21 - 2.14
09/30/21 - 4.69
Operating Margin
03/31/22 - -26,592.46
12/31/21 - -21,145.52
09/30/21 - -13,311.47
Net Margin
03/31/22 - -26,592.46
12/31/21 - -21,145.52
09/30/21 - -13,311.47
Pre-Tax Margin
03/31/22 - -26,592.46
12/31/21 - -21,145.52
09/30/21 - -13,311.47
Book Value
03/31/22 - 0.22
12/31/21 - 0.34
09/30/21 - 0.58
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©